(edited from the skintherapyletter.com article: Stress as an Influencing Factor in Psoriasis)
Psoriasis is a chronic, inflammatory skin disease that affects approximate 2-3% of the general population.1 Although the exact cause is unknown, current evidence suggests that genetic and environmental influences are contributing factors. Among these factors, emotional stress is considered to play an important role in the aggravation and worsening of psoriasis.2
Stress has been indicated as a trigger in many skin conditions, including eczema, acne, and chronic urticaria. With each of these conditions, there are individuals who experience a close chronologic association between stress and worsening of their skin disease, and other individuals for whom their emotional states seem to be unrelated to the natural course of their skin disorder. These two groups are considered “stress responders” and “non-stress responders.” 3
The proportion of psoriasis patients who believe stress affects their skin condition (i.e., “stress responders”) is considerably high, ranging from 37% to 78%. Stress may worsen psoriasis severity and may even lengthen the amount of time to effectively treat the disease.
Breaking this stress cycle may be an important part of any therapeutic approach. Thus, stress reduction through psychotherapy and medication may be useful in treating psoriatic individuals who have high stress levels.
Significance of Stress
Studies define stress along three general categories:
- Major stressful life events (e.g., change of employment, major personal illness, financial problems)
- Psychological or personality difficulties
- Lack of social support5
Regardless of how stress is defined, studies consistently support a relationship between stress and psoriasis.5-12 A majority of individuals consider stress to be the main cause for the worsening of their psoriasis, ranking it above infections, trauma, medications, diet, or weather.6
For example, a study examined 132 psoriasis patients whose psoriasis had completely resolved with anthralin (a medication which is effective at slowing down the growth of skin cells and has anti-inflammatory properties) and were followed over 3 years. 7 Fifty-one patients (39%) recalled specific incidents of stress within 1 month prior to psoriasis aggravation.
A study of 127 psoriasis patients5 found differences between patients who reported that stress flared their psoriasis (stress responders) and patients who reported no association (non-stress responders). Stress-responders described significantly more flare-ups during the 6 months prior to admission, experienced more psoriasis-related daily stress, and relied more upon the approval of others. They also had more severe psoriasis in “emotionally charged” body areas, such as the scalp, face, neck, forearms, hands, and genital region. However, total percentage of body surface affected by psoriasis was not significantly different.
Another study10 found a significant association between stress and disease severity. This prospective study of 62 psoriasis patients determined high levels of daily stressors to be related to an increase in disease severity 4 weeks later.10
Finally, stress may not only worsen psoriasis severity, but it may also adversely affect treatment outcomes. Another study13 found that psychological stress decreased the success rate of treatment in patients undergoing psoralen + ultraviolet A (PUVA) treatment. Patients with high-levels of worry healed with PUVA therapy almost two times slower than those with low-levels of worry.13
Stress and Psoriasis: A Vicious Cycle
Psoriasis itself can serve as a stressor. Psoriasis can be a disfiguring skin disease with much attached social stigmata. Accordingly, some individuals with psoriasis often suffer significant interpersonal and psychological distress. Patients commonly experience difficulties in social interactions, especially in meeting new people and forming romantic relationships. In general, most patients demonstrate adverse psychological consequences, including poor self-esteem, anxiety, depression, and for some, even develop suicidal thoughts.18
As psoriasis can cause considerable stress for patients and increased levels of stress are likely to exacerbate psoriasis, the disease process, thus, becomes a self-perpetuating, vicious cycle.19 Therefore, successful course of treatment should integrate methods of stress reduction, including psychotherapy and pharmacotherapy.
Some relatively easy and feasible stress reduction techniques are yoga, deep breathing exercises, and meditation, just to name a few. More intensive approaches to stress reduction, like psychotherapy or pharmacotherapy, may also be reasonable recommendations. Whether a person is simply experiencing situational stress or suffering from a diagnosable psychiatric disorder, it may be advisable for that individual to consult a mental health professional as long as emotional factors (such as stress) play an important role in the natural history of their psoriasis.
Psychotherapy and Stress Reduction
Psychotherapy may be beneficial for psoriasis patients. Group therapy has been found to be a useful and supportive treatment.21 Group therapy provided patients with knowledge about psoriasis and helped them better cope with their skin disease. Talking to other psoriasis patients enabled participants to learn how to manage disease-related stress and gain self-confidence.21
Case reports have described improvements in psoriasis severity with relaxation and stress reduction techniques, such as hypnosis and thermal biofeedback.22,23
Additionally, in a study of 37 patients treated with ultraviolet B (UVB) or PUVA therapy, it was found that stress reduction helped accelerate the rate of healing. 25
Pharmacotherapy and Stress Reduction
Medications may also be helpful to psoriasis treatment. Studies have demonstrated improvements in psoriasis with oral administration of antidepressants, such as the tricyclic antidepressant (TCA) imipramine (Tofranil®), the monoamine-oxidase inhibitor (MAOI) moclobemide (Manerix®), and buproprion-SR (Wellbutrin®).26-29
Pharmacologic Treatment Recommendations
When pharmacologic treatment is considedered appropriate for stress reduction, SSRIs should be considered for first-line therapy. Despite reported cases of SSRI-associated flares of psoriasis,30-32 SSRIs have certain merits in the treatment of psoriasis patients experiencing depression. As well, these agents may possibly provide additional benefits for non-depressed psoriatics who are stress responders. SSRIs, such as fluoxetine, paroxetine, Zoloft®, and Lexapro®, are generally safe and better tolerated than other classes of antidepressants.33
In addition, anti-anxiety medications may be helpful for short-term use in specific stressful situations for stress responders. For instance, alprazolam (Xanax®) is a fast-acting medication, with both anti-depressant and anti-anxiety effects, that may be beneficial in these situations. Because it has a shorter and more predictable half-life, as compared with other medications, there is less risk of accumulation in the body when used over long periods of time. However, Xanax can be highly sedating and potentially addictive,34 and therefore, treatment should be limited to short-term use on the order of a few weeks to a maximum of a few months.
An extensive number of clinical studies exist that support stress as an exacerbating factor in psoriasis.5-12 People who are identified as stress responders may especially benefit from stress reduction through psychotherapy and/or pharmacotherapy.
1. National Psoriasis Foundation website. About psoriasis: statistics. Available at: http:// www.psoriasis.org/netcommunity/learn/about-psoriasis/statistics. Last accessed: December 14, 2010.
2. Devrimci-Ozguven H, Kundakci TN, Kumbasar H, et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 14(4):267-71 (2000 Jul).
3. Koo JY. Psychodermatology: a practical manual for clinicians. Cur Prob Dermatol 6:204-32 (1995).
4. Picardi A, Abeni D. Stressful life events and skin diseases: disentangling evidence from myth. Psychother Psychosom 70(3):118-36 (2001 May-Jun).
5. Gupta MA, Gupta AK, Kirkby S, et al. A psychocutaneous profile of psoriasis patients who are stress reactors. A study of 127 patients. Gen Hosp Psychiatry 11(3):166-73 (1989 May).
6. Rigopoulos D, Gregoriou S, Katrinaki A, et al. Characteristics of psoriasis in Greece: an epidemiological study of a population in a sunny Mediterranean climate. Eur J Dermatol 20(2):189-95 (2010 Mar-Apr).
7. Seville RH. Psoriasis and stress. Br J Dermatol 97(3):297-302 (1977 Sep).
8. Al’Abadie MS, Kent GG, Gawkrodger DJ. The relationship between stress and the onset and exacerbation of psoriasis and other skin conditions. Br J Dermatol 130(2):199-203 (1994 Feb).
9. Zachariae R, Zachariae H, Blomqvist K, et al. Self-reported stress reactivity and psoriasis-related stress of Nordic psoriasis sufferers. J Eur Acad Dermatol Venereol 18(1):27-36 (2004 Jan).
10. Verhoeven EW, Kraaimaat FW, de Jong EM, et al. Individual differences in the effect of daily stressors on psoriasis: a prospective study. Br J Dermatol 161(2):295-9 (2009 Aug).
11. Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125(1):61-7 (2005 Jul).
12. Jankovic S, Raznatovic M, Marinkovic J, et al. Risk factors for psoriasis: A case-control study. J Dermatol 36(6):328-34 (2009 Jun).
13. Fortune DG, Richards HL, Kirby B, et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 139(6):752-6 (2003 Jun).
14. Arnetz BB, Fjellner B, Eneroth P, et al. Stress and psoriasis: psychoendocrine and metabolic reactions in psoriatic patients during standardized stressor exposure. Psychosom Med 47(6):528-41 (1985 Nov-Dec).
15. Buske-Kirschbaum A, Ebrecht M, Kern S, et al. Endocrine stress responses in TH1-mediated chronic inflammatory skin disease (psoriasis vulgaris)–do they parallel stress-induced endocrine changes in TH2-mediated inflammatory dermatoses (atopic dermatitis)? Psychoneuroendocrinology 31(4):439-46 (2006 May).
16. Evers AW, Verhoeven EW, Kraaimaat FW, et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis. Br J Dermatol 163(5):986-91 (2010 Nov).
17. Richards HL, Ray DW, Kirby B, et al. Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis. Br J Dermatol 153(6):1114-20 (2005 Dec).
18. Russo PA, Ilchef R, Cooper AJ. Psychiatric morbidity in psoriasis: a review. Australas J Dermatol 45(3):155-9 (2004 Aug).
19. Kimball AB, Jacobson C, Weiss S, et al. The psychosocial burden of psoriasis. Am J Clin Dermatol 6(6):383-92 (2005).
20. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association (2000).
21. Seng TK, Nee TS. Group therapy: a useful and supportive treatment for psoriasis patients. Int J Dermatol 36(2):110-2 (1997 Feb).
22. Winchell SA, Watts RA. Relaxation therapies in the treatment of psoriasis and possible pathophysiologic mechanisms. J Am Acad Dermatol 18(1 Pt 1):101-4 (1988 Jan).
23. Griffiths CE, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol 26(4):338-42 (2001 Jun).
24. Price ML, Mottahedin I, Mayo PR. Can psychotherapy help patients with psoriasis? Clin Exp Dermatol 16(2):114-7 (1991 Mar).
25. Kabat-Zinn J, Wheeler E, Light T, et al. Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA). Psychosom Med 60(5):625-32 (1998 Sep-Oct).
26. Hardman R, Hopkins EJ, Pye AM, Solomon M, Solomon S. A trial of imipramine in the treatment of psoriasis. J Coll Gen Pract 10(3):315-6 (1965 Nov).
27. Hebel E. [Treatment of psoriasis with imipramine (Tofranil)] . Ugeskr Laeger 128(1):20-1 (1966 Jan 6).
28. Alpsoy E, Ozcan E, Cetin L, et al. Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. J Am Acad Dermatol 38(2 Pt 1):197-200 (1998 Feb).
29. Modell JG, Boyce S, Taylor E, et al. Treatment of atopic dermatitis and psoriasis vulgaris with bupropion-SR: a pilot study. Psychosom Med 64(5):835-40 (2002 Sep-Oct).
30. Tamer E, Gur G, Polat M, et al. Flare-up of pustular psoriasis with fluoxetine: possibility of a serotoninergic influence? J Dermatolog Treat 20(3):1-3 (2009).
31. Hemlock C, Rosenthal JS, Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 26(2):211-2 (1992 Feb).
32. Osborne SF, Stafford L, Orr KG. Paroxetine-associated psoriasis. Am J Psychiatry 159(12):2113 (2002 Dec).
33. Katon W, Ciechanowski P. Initial treatment of depression in adults. In: UpToDate. Waltham, MA. Available at: http://www.uptodate.com/patients/content/topic.do?topic Key=~G3004xxXjAXnf&selectedTitle=3%7E150. Last accessed: December 14, 2010.
34. DuPont RL, Greene W, Lydiard R. Sedatives and hypnotics: pharmacology and epidemiology. In: UpToDate. Waltham, MA. Available at: http://www.uptodate. com/patients/content/topic.do?topicKey=~kzgzCmVotMPtg. Last accessed: December 14, 2010.